HIV-1 Vif N-terminal Motif is required for recruitment of Cul5 to Suppress APOBEC3

Retrovirology

Volumn 11, Issue 1, 2014, Pages

  Evans, Sean L ^a   Schön, Arne ^b   Gao, Qimeng ^a   Han, Xue ^a,c   Zhou, Xiaohong ^a,c,d   Freire, Ernesto ^b   Yu, Xiao Fang ^a,c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c TIANJIN UNIVERSITY   (China)

^d THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; AMINO ACID; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CORE BINDING FACTOR BETA; CULLIN; ELONGIN BC; HISTAMINE; HISTIDINE; METHIONINE; PROTEIN CUL5; TYROSINE; UNCLASSIFIED DRUG; VALINE; VIF PROTEIN; CULLIN 5; ELONGIN B; ELONGIN C;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; CIRCULAR DICHROISM; GEL PERMEATION CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOTHERMAL TITRATION CALORIMETRY; NONHUMAN; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; WILD TYPE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; MAMMAL CELL; POINT MUTATION; RESIDUE ANALYSIS; VIRUS INFECTIVITY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

CULLIN PROTEINS; CYTIDINE DEAMINASE; CYTOSINE DEAMINASE; HIV-1; HUMANS; IMMUNE EVASION; PROTEIN INTERACTION MAPPING; PROTEOLYSIS; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84892410245     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-11-4     Document Type: Article

References (40)

1. Malim MH, Emerman M. HIV-1 accessory proteins-ensuring viral survival in a hostile environment. Cell Host Microbe 2008, 3(6):388-398. 10.1016/j.chom.2008.04.008, 18541215.
2. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418(6898):646-650. 10.1038/nature00939, 12167863.
3. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 2003, 424(6944):94-98. 10.1038/nature01707, 1350966, 12808465.
4. Sheehy AM, Gaddis NC, Malim MH. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 2003, 9(11):1404-1407. 10.1038/nm945, 14528300.
5. Oberste MS, Gonda MA. Conservation of amino-acid sequence motifs in lentivirus Vif proteins. Virus Genes 1992, 6(1):95-102. 10.1007/BF01703760, 1312756.
6. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 2003, 302(5647):1056-1060. 10.1126/science.1089591, 14564014.
7. Yu Y, Xiao Z, Ehrlich ES, Yu X, Yu XF. Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev 2004, 18(23):2867-2872. 10.1101/gad.1250204, 534647, 15574593.
8. Mehle A, Strack B, Ancuta P, Zhang C, McPike M, Gabuzda D. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem 2004, 279(9):7792-7798. 10.1074/jbc.M313093200, 14672928.
9. Kobayashi M, Takaori-Kondo A, Miyauchi Y, Iwai K, Uchiyama T. Ubiquitination of APOBEC3G by an HIV-1 Vif-Cullin5-Elongin B-Elongin C complex is essential for Vif function. J Biol Chem 2005, 280(19):18573-18578. 10.1074/jbc.C500082200, 15781449.
10. Jager S, Kim DY, Hultquist JF, Shindo K, LaRue RS, Kwon E, Li M, Anderson BD, Yen L, Stanley D, Mahon C, Kane J, Franks-Skiba K, Cimermancic P, Burlingame A, Sali A, Craik CS, Harris RS, Gross JD, Krogan NJ. Vif hijacks CBF-beta to degrade APOBEC3G and promote HIV-1 infection. Nature 2011, 481(7381):371-375. 3310910, 22190037.
11. Zhang W, Du J, Evans SL, Yu Y, Yu XF. T-cell differentiation factor CBF-beta regulates HIV-1 Vif-mediated evasion of host restriction. Nature 2011, 481(7381):376-379.
12. Salter JD, Lippa GM, Belashov IA, Wedekind JE. Core-binding factor beta increases the affinity between human cullin 5 and HIV-1 Vif within an E3 ligase complex. Biochemistry 2012, 51(44):8702-4. 10.1021/bi301244z, 3598157, 23098073.
13. Zhou X, Evans SL, Han X, Liu Y, Yu XF. Characterization of the interaction of full-length HIV-1 Vif protein with its key regulator CBFbeta and CRL5 E3 ubiquitin ligase components. PLoS One 2012, 7(3):e33495. 10.1371/journal.pone.0033495, 3316577, 22479405.
14. Du J, Zhao K, Rui Y, Li P, Zhou X, Zhang W, Yu XF. Differential requirements for HIV-1 Vif-mediated APOBEC3G degradation and RUNX1-mediated transcription by core binding factor beta. J Virol 2013, 87(3):1906-1911. 10.1128/JVI.02199-12, 3554157, 23175372.
15. Hultquist JF, Binka M, LaRue RS, Simon V, Harris RS. Vif proteins of human and simian immunodeficiency viruses require cellular CBFbeta to degrade APOBEC3 restriction factors. J Virol 2012, 86(5):2874-2877. 10.1128/JVI.06950-11, 3302251, 22205746.
16. Kim DY, Kwon E, Hartley PD, Crosby DC, Mann S, Krogan NJ, Gross JD. CBFbeta stabilizes HIV Vif to counteract APOBEC3 at the expense of RUNX1 target gene expression. Mol Cell 2013, 49(4):632-644. 10.1016/j.molcel.2012.12.012, 3582769, 23333304.
17. Mehle A, Goncalves J, Santa-Marta M, McPike M, Gabuzda D. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev 2004, 18(23):2861-2866. 10.1101/gad.1249904, 534646, 15574592.
18. Luo K, Xiao Z, Ehrlich E, Yu Y, Liu B, Zheng S, Yu XF. Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc Natl Acad Sci USA 2005, 102(32):11444-11449. 10.1073/pnas.0502440102, 1182177, 16076960.
19. Paul I, Cui J, Maynard EL. Zinc binding to the HCCH motif of HIV-1 virion infectivity factor induces a conformational change that mediates protein-protein interactions. Proc Natl Acad Sci U S A 2006, 103(49):18475-18480. 10.1073/pnas.0604150103, 1693687, 17132731.
20. Xiao Z, Ehrlich E, Yu Y, Luo K, Wang T, Tian C, Yu XF. Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology 2006, 349(2):290-299. 10.1016/j.virol.2006.02.002, 16530799.
21. Xiao Z, Xiong Y, Zhang W, Tan L, Ehrlich E, Guo D, Yu XF. Characterization of a novel Cullin5 binding domain in HIV-1 Vif. J Mol Biol 2007, 373(3):541-550. 10.1016/j.jmb.2007.07.029, 17869271.
22. Stanley BJ, Ehrlich ES, Short L, Yu Y, Xiao Z, Yu XF, Xiong Y. Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly. J Virol 2008, 82(17):8656-8663. 10.1128/JVI.00767-08, 2519636, 18562529.
23. Mehle A, Thomas ER, Rajendran KS, Gabuzda D. A zinc-binding region in Vif binds Cul5 and determines cullin selection. J Biol Chem 2006, 281(25):17259-17265. 10.1074/jbc.M602413200, 16636053.
24. Bergeron JR, Huthoff H, Veselkov DA, Beavil RL, Simpson PJ, Matthews SJ, Malim MH, Sanderson MR. The SOCS-box of HIV-1 Vif interacts with ElonginBC by induced-folding to recruit its Cul5-containing ubiquitin ligase complex. PLoS Pathog 2010, 6(6):e1000925. 10.1371/journal.ppat.1000925, 2880568, 20532212.
25. Chen G, He Z, Wang T, Xu R, Yu XF. A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G. J Virol 2009, 83(17):8674-8682. 10.1128/JVI.00653-09, 2738209, 19535450.
26. Dang Y, Wang X, Zhou T, York IA, Zheng YH. Identification of a novel WxSLVK motif in the N terminus of human immunodeficiency virus and simian immunodeficiency virus Vif that is critical for APOBEC3G and APOBEC3F neutralization. J Virol 2009, 83(17):8544-8552. 10.1128/JVI.00651-09, 2738151, 19535447.
27. Mehle A, Wilson H, Zhang C, Brazier AJ, McPike M, Pery E, Gabuzda D. Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding. J Virol 2007, 81(23):13235-13241. 10.1128/JVI.00204-07, 2169136, 17898068.
28. He Z, Zhang W, Chen G, Xu R, Yu XF. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction. J Mol Biol 2008, 381(4):1000-1011. 10.1016/j.jmb.2008.06.061, 18619467.
29. Tian C, Yu X, Zhang W, Wang T, Xu R, Yu XF. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J Virol 2006, 80(6):3112-3115. 10.1128/JVI.80.6.3112-3115.2006, 1395459, 16501124.
30. Russell RA, Pathak VK. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J Virol 2007, 81(15):8201-8210. 10.1128/JVI.00395-07, 1951317, 17522216.
31. Walker RC, Khan MA, Kao S, Goila-Gaur R, Miyagi E, Strebel K. Identification of dominant negative human immunodeficiency virus type 1 Vif mutants that interfere with the functional inactivation of APOBEC3G by virus-encoded Vif. J Virol 2010, 84(10):5201-5211. 10.1128/JVI.02318-09, 2863814, 20219919.
32. Donahue JP, Vetter ML, Mukhtar NA, D'Aquila RT. The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation. Virology 2008, 377(1):49-53. 10.1016/j.virol.2008.04.017, 2474554, 18499212.
33. Wolfe LS, Stanley BJ, Liu C, Eliason WK, Xiong Y. Dissection of the HIV Vif interaction with human E3 ubiquitin ligase. J Virol 2010, 84(14):7135-7139. 10.1128/JVI.00031-10, 2898223, 20463065.
34. Andrade MA, Chacon P, Merelo JJ, Moran F. Evaluation of secondary structure of proteins from UV circular dichroism spectra using an unsupervised learning neural network. Protein Eng 1993, 6(4):383-390. 10.1093/protein/6.4.383, 8332596.
35. Whitmore L, Wallace BA. Protein secondary structure analyses from circular dichroism spectroscopy: methods and reference databases. Biopolymers 2008, 89(5):392-400. 10.1002/bip.20853, 17896349.
36. Wang X, Wang X, Zhang H, Lv M, Zuo T, Wu H, Wang J, Liu D, Wang C, Zhang J, Li X, Wu J, Yu B, Kong W, Yu X. Interactions between HIV-1 Vif and human ElonginB-ElonginC are important for CBF-beta binding to Vif. Retrovirology 2013, 10(1):94. 10.1186/1742-4690-10-94, 3765967, 23988114.
37. Nagao T, Yamashita T, Miyake A, Uchiyama T, Nomaguchi M, Adachi A. Different interaction between HIV-1 Vif and its cellular target proteins APOBEC3G/APOBEC3F. J Med Invest 2010, 57(1-2):89-94.
38. Yamashita T, Kamada K, Hatcho K, Adachi A, Nomaguchi M. Identification of amino acid residues in HIV-1 Vif critical for binding and exclusion of APOBEC3G/F. Microbes Infect 2008, 10(10-11):1142-1149.
39. Zhang H, Pomerantz RJ, Dornadula G, Sun Y. Human immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process. J Virol 2000, 74(18):8252-8261. 10.1128/JVI.74.18.8252-8261.2000, 116333, 10954522.
40. Yedavalli VR, Ahmad N. Low conservation of functional domains of HIV type 1 vif and vpr genes in infected mothers correlates with lack of vertical transmission. AIDS Res Hum Retroviruses 2001, 17(10):911-923. 10.1089/088922201750290032, 11461677.